## **Nectar Lifesciences Ltd.**



Ref.: NLL/CS/2024- 419 October 21, 2024

To

 National Stock Exchange of India Limited Listing Department,
 Exchange Plaza, Bandra Kurla Complex,
 Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship
Department, P J Towers, Dalal
Street, Mumbai 400 001
Scrip Code: 532649

Sub: Regulation 30 of the Securities and Exchange of Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Dear Sir/ Madam,

This is with reference to point no. 2 of Annexure 1 of letter no. NLL/CS/2024-416 dated October 15, 2024, vide which the Company had informed pending Litigation(s) as required under Regulation 30 of the LODR Regulations.

Pursuant to captioned regulations, please find enclosed herewith necessary disclosures in prescribed format for details/ updation of Litigation and/ or orders passed by any regulatory authority or judicial body as per Annexure-A.

The relevant extract of letter no. NLL/CS/2024-416 dated October 15, 2024, is attached as an Annexure B.

This is for your information and record please.

Thanking you,

Yours faithfully,
For **Nectar Lifesciences Limited** 

(Neha <mark>Vais</mark>hnav)

Company Secretary & Compliance Officer

Encl.: as above

## **Nectar Lifesciences Ltd.**



Annexure A

The Details of Litigation and/ or order passed by regulatory authority or judicial body for or against Nectar Lifesciences Limited ("Company")

At th	ne time of becoming party		
Sr no.	Brief details of litigation and action taken or order passed	Expected Financial Implication	Quantum of claims, if any
1.	Nectar Lifesciences Limited		
	Name of Opposite Party: Principal Commissioner of Income Tax (Central), Gurugram  Forum by which order is passed: Hon'ble Delhi High Court  Brief Detail of the Case: Tax relief of Rs.1,43,39,161/- (on dividend income received from subsidiary company in Sri Lanka) given by ITAT, Chandigarh, for FY 2004-05, had been contested by Income Tax Department in Hon'ble Delhi High Court.  Delhi High Court, vide its order dated 16.10.2024, has dismissed the appeal of Income Tax Department for AY 2005-06, because the appeal was below the threshold limit of Rs. 2 Crores as stipulated in Circular dated 17.09.2024.	Tax relief against the claim of Rs. 1,43,39,161/-has been provided by Delhi High Court as it has dismissed the appeal of Income Tax Department.	NIL
	The formal order of Court is uploaded on its website on October 21, 2024.		

## **Nectar Lifesciences Ltd.**



Annexure B

The Details of Litigation and/ or order passed by regulatory authority or judicial body for or against Nectar Lifesciences Limited ("Company")

At th	ne time of becoming party				
Sr no.	Brief details of litigation and action taken or order passed	Expected Financial Implication	Quantum of claims, if any		
2.	Name of Opposite Party: Principal Commissioner of Income Tax (Central), Gurugram Forum where Pending: Hon'ble Delhi High Court  Brief Detail of the Case: Tax relief of Rs.1,43,39,161/- (on dividend income received from subsidiary company in Sri Lanka) given by ITAT, Chandigarh, for FY 2004-05, has been contested by Income Tax Department in Hon'ble Delhi High Court. The above relief was allowed by the ITAT Chandigarh on the basis of judgement of Hon'ble Supreme Court in the case of Torquoise Investment & Finance Ltd. vs. DCIT. The Company will request Delhi High Court to ask Income Tax Department to withdraw this case in view of CBDT circular No. 9/2024 dated 17.09.2024.  Date of hearing is fixed for 16.10.2024.  We became aware of this case on 15.10.2024 suomoto without receipt of any notice from Delhi High	Expected financial implication will be Rs.1,43,39,161/-if Hon'ble Delhi High Court decides against the Company.	As disclosed in financial implications column.		